TRDX Trend Exploration Inc (PK)

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. ("TRDX" or the "Company") (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX") which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.

In addition, the Company provides the following details regarding the recently executed Definitive Sublicense Agreement ("Definitive") with Montreal-based Genesis Biopharma, Inc. ("Genesis").

General Terms:

Financing        TRDX has committed to a financing of $800,000 for the
                 continued R&D of Genesis' Painful Diabetic Neurapathy
                 ("PDN") solution

                 The financing can be completed in tranches, with each
                 tranche resulting in a pro-rated ownership of DiabetRX.

First Tranche    $60,000 required to maintain sublicense and take possession
                 of the first 7.5% of DiabetRX

Initial Closing  The Initial Closing is based on, amongst other items, the
                 completion of customary due diligence by the parties

Final Closing    Final Closing is defined as the completion of the $800,000
                 financing for the development of the PDN solution

Dr. Jan Stahl, CEO of TRDX, commented: "Since the signing of the Definitive Agreement, I am very happy with the progress we have made with Genesis. We feel confident in the current steps we are taking to complete the Initial Closing and first Tranche financing. We view DiabetRX as a long term investment with large potential and look forward to the Final Closing."

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. (www.genesisbiopharma.com) is a Canadian corporation founded in 2007 to exploit the commercial potential for the therapeutic use of peptidomimetic (modified amino acid peptides) compounds. Amino acids are the building blocks of proteins, which are found in every cell. Proteins consist of extremely long and complex amino acid chains. In contrast, a peptide is a short string of amino acids, joined by chemical bonds (also called "amide bonds").

About SCIMEDENT f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX)

SciMeDent is a company focused on being a leading developer and marketer of products and services for medicine, dentistry and life sciences. SciMeDent plans to achieve growth initially through mergers and acquisitions.

Cautionary Statement Regarding Forward-Looking Statements

A number of statements contained in this press release are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the sufficiency of existing capital resources, technological or industry changes and uncertainties related to the development of the Company's business model. The actual results the Company may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.

Contact: SciMeDent Health Corp. f/k/a Trend Exploration, Inc. dmyers@cadenceconsultingllc.com 1-866-383-1374